TRIN 2755 is the clinical candidate of TRIN Pharma.
 --is based on a new chemistry with solid IP platform
--has shown high efficacy against tumors and metastasis of melanoma-
 --and colon canrcinoma. The vast majority of animals treated with
--TRIN 2755 reached complete and stable remission at well tolerated doses
--accumulates selectively in tumor cells and exerts rapid metabolic clearance
--at relevant doses, side effects were negligible in early toxicology studies
Target date for the entry into clinical studies is the first quarter of 2009. |
